Biomics Biopharma (ASX:BBM) Asset Turnover: 0.00 (As of . 20)


What is Biomics Biopharma Asset Turnover?

Biomics Biopharma ASX:BBM Asset Turnover is 0.00 as of . 20.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Biomics Biopharma's Revenue for the six months ended in . 20 was A$ Mil. Biomics Biopharma's Total Assets for the quarter that ended in . 20 was A$ Mil. Therefore, Biomics Biopharma's Asset Turnover for the quarter that ended in . 20 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Biomics Biopharma's annualized ROE % for the quarter that ended in . 20 was %. It is also linked to ROA % through Du Pont Formula. Biomics Biopharma's annualized ROA % for the quarter that ended in . 20 was %.

Biomics Biopharma  (ASX:BBM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Biomics Biopharma's annulized ROE % for the quarter that ended in . 20 is

ROE %**(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*(/ )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

Note: The Net Income data used here is two times the semi-annual (. 20) net income data. The Revenue data used here is two times the semi-annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Biomics Biopharma's annulized ROA % for the quarter that ended in . 20 is

ROA %(Q: . 20 )
=Net Income/Total Assets
=/
=(Net Income / Revenue)*(Revenue / Total Assets)
=( / )*( / )
=Net Margin %*Asset Turnover
= %*
= %

Note: The Net Income data used here is two times the semi-annual (. 20) net income data. The Revenue data used here is two times the semi-annual (. 20) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.

Biomics Biopharma Asset Turnover Related Terms

Biomics Biopharma Asset Turnover Historical Data

* Premium members only.

The historical data trend for Biomics Biopharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomics Biopharma Asset Turnover Chart

Biomics Biopharma Annual Data
Trend
Asset Turnover

Biomics Biopharma Semi-Annual Data
Asset Turnover

Biomics Biopharma Asset Turnover Competitor Comparison

For the Biotechnology subindustry, Biomics Biopharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomics Biopharma Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomics Biopharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Biomics Biopharma's Asset Turnover falls into.


Biomics Biopharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Biomics Biopharma's Asset Turnover for the fiscal year that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: . 20 )/( (Total Assets (A: . 20 )+Total Assets (A: . 20 ))/ count )
=/( (+)/ )
=/
=

Biomics Biopharma's Asset Turnover for the quarter that ended in . 20 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: . 20 )/( (Total Assets (Q: . 20 )+Total Assets (Q: . 20 ))/ count )
=/( (+)/ )
=/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Biomics Biopharma (ASX:BBM) has a Asset Turnover of 0.00 as of . 20. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Biomics Biopharma and its competitors.
Is Biomics Biopharma's Asset Turnover too high?
Biomics Biopharma's current Asset Turnover is 0.00.
How does Biomics Biopharma's Asset Turnover compare to competitors?
Biomics Biopharma's Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Biomics Biopharma and its competitors. Biomics Biopharma's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomics Biopharma stock overvalued right now?
Biomics Biopharma (ASX:BBM) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Biomics Biopharma (ASX:BBM), the current Asset Turnover is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomics Biopharma Business Description

Address 1 Macquarie Place, Level 36, Gateway Tower, Sydney, NSW, AUS, 2000
Biomics Biopharma Ltd is a near-clinical-stage biopharmaceutical company in developing and commercialising double stranded ribonucleic acid (dsRNA) based innovative products for unmet medical needs.